KBC Group’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
Other funds holding SUPN
VPM
VCM
NAMI
AC
KBC Group's SUPN Position: Q1 2026 in Review
KBC Group held its Supernus Pharmaceuticals (SUPN) position steady in Q1 2026 at 1,774 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #1371.
KBC Group first reported a position in SUPN in Q2 2017 and has held it in 26 quarters since. The position peaked at $1.3M in Q1 2018. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- KBC Group held 1,774 shares of Supernus Pharmaceuticals worth $92K as of Q1 2026.
- KBC Group left its Supernus Pharmaceuticals share count unchanged in Q1 2026.
- Supernus Pharmaceuticals made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1371 holding.
- KBC Group first reported a position in Supernus Pharmaceuticals in Q2 2017 and has held it in 26 quarters since.
- KBC Group's Supernus Pharmaceuticals position peaked at $1.3M in Q1 2018.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.